CDXS Codexis, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 11, 2026
$1,36
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$0,9652tyg. minimum
$2,9852tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$124M
P/E (TTM)
-4.2
EPS (TTM)
$-0.32
Przychody (TTM)
$78M
Twoje odznaki
Zakres 52 tyg.
$1–$3
Ocena Analityków
BUY
Cena Docelowa
$6
P/E
-4.2
ROE
-69.4%
Marża Zysku Netto
-39.6%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
CDXS Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$1.36
Kapitalizacja Rynkowa (MRQ)
$124M
P/E (TTM)
-4.2
EPS (TTM)
$-0.32
Przychody (TTM)
$78M
ROE (TTM)
-69.4%
D/E Dług/Kapitał (MRQ)
1.2
Zakres 52 tyg.
$1–$3
CDXS Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O Codexis, Inc. - Common Stock Przegląd firmy z Wikipedii
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
History
Codexis is based in Redwood City, CA and was incorporated in 2002. It went public in April 2010 on NASDAQ, and in October, acquired Maxygen's MolecularBreeding technology portfolio.
Pharmaceutical
Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor. It then won a second time in 2010 for its work with Merck & Co. on the active ingredient in Januvia.
Nutrition
In 2017, the company entered a partnership with Tate & Lyle to provide research and development for the production of new ingredients. That same year, Codexis announced a collaboration with Nestle to provide enzymes for metabolic disorders.
Biotherapeutics
In 2017, Codexis developed a recombinant phenylalanine ammonia-lyase (PAL) enzyme, to act as a substitute phenylalanine hydroxylase (PAH) enzyme for people who suffer from phenylketonuria. The enzyme was in-licensed by Nestle Health Sciences.
In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders.
Life science
In June 2020, they announced a partnership with Molecular Assemblies to engineer enzymes for DNA synthesis.
Technology
Codexis uses directed evolution to develop its enzymes. Using this method, scientists genetically engineer genes, then screen the enzymes produced to see if it creates the properties needed for a specific reaction. Their protein engineering platform, called CodeEvolver, uses machine learning and high-throughput experimentation to learn protein sequence changes and their impacts on protein function.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaLife Sciences Tools & Services
pracownicy146
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$70M2016-12-31 → 2025-12-31
EPS$-0.502019-12-31 → 2025-12-31
Wolny przepływ pieniężny$-24M2016-12-31 → 2025-12-31
Marża netto-39.6%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | CDXS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -4.2średnia z 5 lat ≈-23.0 | ≈-23.0 | · | · | |
| P/S (TTM) | 1.6średnia z 5 lat ≈6.7 | ≈6.7 | 4.2 | Niedowartościowany | |
| P/B (MRQ) | 3.8średnia z 5 lat ≈5.1 | ≈5.1 | 0.9 | Zawyżona wycena | |
| EV / EBITDA (TTM) | -4.9 | · | · | · | |
| Cena / FCF (TTM) | -10.2średnia z 5 lat ≈2.7 | ≈2.7 | · | · | |
| Cena / Przepływy pieniężne (TTM) | -11.9średnia z 5 lat ≈-27.0 | ≈-27.0 | · | · | |
| EV / Przychody (TTM) | 1.4 | · | · | · | |
| EV / FCF (TTM) | -9.1 | · | · | · | |
| Price / Tangible Book (Cena / Wartość księgowa materialna) | 2.6średnia z 5 lat ≈5.3 | ≈5.3 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | CDXS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | -35.6%średnia z 5 lat ≈-60.4% | ≈-60.4% | -140.7% | Najwyższa półka | |
| Marża EBITDA (TTM) | -28.9%średnia z 5 lat ≈-57.2% | ≈-57.2% | -140.7% | Najwyższa półka | |
| Marża przed opodatkowaniem (TTM) | -39.5%średnia z 5 lat ≈-65.0% | ≈-65.0% | -122.0% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | -39.6%średnia z 5 lat ≈-65.1% | ≈-65.1% | -140.9% | Najwyższa półka | |
| ROA (TTM) | -23.8%średnia z 5 lat ≈-27.5% | ≈-27.5% | -22.2% | Słaby | |
| ROE (TTM) | -69.4%średnia z 5 lat ≈-59.3% | ≈-59.3% | -34.9% | Słaby | |
| ROIC | -46.1%średnia z 5 lat ≈-44.8% | ≈-44.8% | -40.5% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | CDXS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 1.2 | · | · | · | |
| Wskaźnik bieżący (MRQ) | 3.1średnia z 5 lat ≈3.8 | ≈3.8 | 6.5 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 3.1średnia z 5 lat ≈3.1 | ≈3.1 | 1.8 | Silna płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 1.0 | · | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | CDXS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 18.6%średnia z 5 lat ≈7.6% | ≈7.6% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | -20.2%średnia z 5 lat ≈-12.3% | ≈-12.3% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 0.38% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | CDXS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.5średnia z 5 lat ≈0.5 | ≈0.5 | 0.4 | Najwyższa półka | |
| Inventory Turnover (Rotacja zapasów) | 5.2średnia z 5 lat ≈12.5 | ≈12.5 | 1.9 | Najwyższa półka | |
| Revenue / Employee (Przychody / pracownika) | ≈$482.1K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
15.7%
Następny raport
Lis 04, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 11, 2026 | $-0.13 | $-0.14 | 7.7% |
| 31 marca 2026 | Maj 12, 2026 | $-0.10 | $-0.14 | 28.3% |
| 31 grudnia 2025 | $0.11 | $-0.04 | 357.0% | |
| 30 września 2025 | $-0.22 | $-0.15 | -45.2% | |
| 30 czerwca 2025 | $-0.16 | $-0.19 | 16.8% | |
| 31 marca 2025 | $-0.25 | $-0.24 | -3.3% | |
| 31 grudnia 2024 | $-0.13 | $-0.04 | -251.4% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70M | $59M | $70M | $139M | $105M | $69M | $68M | $61M | $50M | $49M | $42M | $35M | |
| Cost of Revenue | $9M | $16M | $13M | $38M | $22M | $14M | $16M | $13M | $14M | $10M | $7M | $10M | |
| R&D Expense | $52M | $46M | $59M | $80M | $56M | $44M | $34M | $30M | $30M | $22M | $21M | $23M | |
| SG&A Expense | $47M | $55M | $53M | $52M | $49M | $35M | $32M | $29M | $29M | $25M | $22M | $22M | |
| Operating Expenses | $112M | $118M | $138M | $173M | $127M | $93M | $81M | $72M | $73M | $57M | $50M | $54M | |
| Operating Income | $-42M | $-59M | $-68M | $-35M | $-23M | $-24M | $-13M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Interest Income | $3M | $4M | $4M | $1M | $459.0K | $405.0K | $1M | $671.0K | $147.0K | $60.0K | $19.0K | $18.0K | |
| Other Non-op | $-5M | $-10M | $-12M | $124.0K | $1M | $-156.0K | $-656.0K | $-291.0K | $-92.0K | $-94.0K | · | · | |
| Pretax Income | $-44M | $-65M | $-76M | $-33M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Income Tax | $47.0K | $34.0K | $69.0K | $276.0K | $189.0K | $339.0K | $17.0K | $-37.0K | $81.0K | $-40.0K | $-338.0K | $-256.0K | |
| Net Income | $-44M | $-65M | $-76M | $-34M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| EPS (Basic) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · | |
| EPS (Diluted) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · | |
| Shares (Basic) | 87,142,000 | 73,408,000 | 68,131,000 | 65,344,000 | 64,568,000 | 59,360,000 | 56,525,000 | · | · | · | · | · | |
| Shares (Diluted) | 87,142,000 | 73,408,000 | 68,131,000 | 65,344,000 | 64,568,000 | 59,360,000 | 56,525,000 | · | · | · | · | · | |
| EBITDA | $-36M | $-54M | $-68M | $-35M | $-23M | $-24M | $-13M | $-11M | $-23M | $-9M | $-8M | $-19M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51M | $19M | $65M | $114M | $117M | $149M | $90M | $53M | $31M | $19M | $23M | $26M | |
| Short-term Investments | $27M | $54M | $0 | · | · | · | · | · | · | · | · | · | |
| Receivables | · | · | $10M | $32M | $25M | $14M | $9M | $12M | $11M | $6M | $7M | $4M | |
| Inventory | $2M | $2M | $3M | $2M | $1M | $964.0K | $371.0K | $589.0K | $1M | $825.0K | $992.0K | $1M | |
| Prepaid Expense | $6M | $4M | $5M | $5M | $6M | $3M | $3M | $1M | $984.0K | $1M | $1M | $1M | |
| Other Current Assets | $500.0K | $500.0K | $600.0K | $700.0K | · | · | · | · | · | · | · | · | |
| Current Assets | $97M | $99M | $93M | $163M | $162M | $184M | $114M | $68M | $45M | $27M | $33M | $33M | |
| PP&E (Net) | $13M | $14M | $15M | $23M | $21M | $10M | $6M | $5M | $3M | $2M | $3M | $4M | |
| PP&E (Gross) | $58M | $55M | $55M | $62M | $57M | $43M | $40M | $38M | $35M | $34M | $35M | $37M | |
| Accum. Depreciation | $45M | $41M | $39M | $40M | $36M | $33M | $33M | $33M | $32M | $32M | $32M | $31M | |
| Goodwill | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Intangibles | · | · | · | · | · | · | · | · | · | $0 | $3M | $6M | |
| Other Non-current Assets | $883.0K | $1M | $1M | $350.0K | $276.0K | $294.0K | $178.0K | $1M | $302.0K | $259.0K | $310.0K | $294.0K | |
| Total Assets | $148M | $149M | $137M | $250M | $246M | $222M | $149M | $79M | $54M | $36M | $45M | $48M | |
| Accounts Payable | $2M | $3M | $6M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $5M | |
| Accrued Liabilities | $3M | $6M | $5M | $15M | $13M | $10M | $7M | $5M | $4M | $2M | $2M | $3M | |
| Current Liabilities | $25M | $24M | $36M | $49M | $33M | $25M | $15M | $18M | $25M | $12M | $15M | $14M | |
| Capital Leases | $30M | $28M | $12M | $38M | $44M | $22M | $25M | $61.0K | $302.0K | · | · | · | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $3M | |
| Total Liabilities | $97M | $82M | $50M | $106M | $82M | $52M | $44M | $23M | $29M | $17M | $22M | · | |
| Long-term Debt | $40M | $29M | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $40M | $29M | · | · | · | · | · | · | $302.0K | · | · | · | |
| Common Stock | $9.0K | $8.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | |
| Paid-in Capital | $657M | $630M | $584M | $566M | $552M | $537M | $448M | $387M | $340M | $311M | $306M | $302M | |
| Retained Earnings | $-607M | $-563M | $-498M | $-421M | $-388M | $-366M | $-342M | $-330M | $-315M | $-292M | $-284M | $-276M | |
| AOCI | $8.0K | $52.0K | $0 | · | · | · | · | $0 | $-472.0K | $0 | $405.0K | $-142.0K | |
| Stockholders' Equity | $51M | $67M | $87M | $145M | $164M | $170M | $106M | $56M | $25M | $19M | $23M | $26M | |
| Liabilities + Equity | $148M | $149M | $137M | $250M | $246M | $222M | $149M | $79M | $54M | $36M | $45M | $48M | |
| Shares Outstanding | 90,478,000 | 81,850,000 | 69,905,000 | 65,811,000 | 65,109,000 | 64,283,000 | 58,877,000 | 54,065,000 | 48,365,000 | 41,255,000 | 40,343,000 | 39,563,000 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $5M | $5M | $6M | $5M | · | · | · | · | · | · | · | · | |
| Stock-based Comp | $10M | $13M | $10M | $15M | $12M | $8M | $7M | $8M | $7M | $6M | $5M | $5M | |
| Deferred Tax | $-3.0K | $-2.0K | $0 | $-7.0K | $-9.0K | $-8.0K | $-6.0K | $-29.0K | $12.0K | $-31.0K | $-330.0K | $110.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $0 | $3M | $3M | $3M | |
| Restructuring | $3M | $0 | $3M | $3M | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $10M | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-19M | $-49M | $-53M | $11M | $-14M | $-16M | $-13M | $-14M | $-9M | $-2M | $-433.0K | $321.0K | |
| CapEx | $4M | $4M | $4M | $8M | $14M | $4M | $4M | $3M | $985.0K | $888.0K | $1M | $302.0K | |
| Investing Cash Flow | $24M | $-57M | $-5M | $-14M | $-21M | $-6M | $-4M | $-3M | $-983.0K | $-846.0K | $-1M | $5M | |
| Debt Issued | $10M | $30M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $10M | $30M | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $17M | $31M | $9M | $0 | $0 | $86M | $0 | $37M | $24M | $0 | $0 | $9.0K | |
| Net Stock Activity | $17M | $31M | $9M | $0 | $0 | $86M | $50M | · | $24M | $0 | $0 | $9.0K | |
| Financing Cash Flow | $28M | $61M | $8M | $-575.0K | $4M | $81M | $54M | $39M | $22M | $-490.0K | $-2M | $-611.0K | |
| Net Change in Cash | $32M | $-46M | $-49M | $-3M | $-32M | $59M | $38M | $22M | $12M | $-3M | $-3M | $4M | |
| Taxes Paid | · | $17.0K | $194.0K | $100.0K | $102.0K | $312.0K | $5.0K | $5.0K | $32.0K | $5.0K | $8.0K | $15.0K | |
| Free Cash Flow | $-24M | $-54M | $-57M | $3M | $-28M | $-20M | $-16M | $-17M | $-10M | $-4M | $-2M | $19.0K |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -59.3% | -98.6% | -97.0% | -25.2% | -21.7% | -34.6% | -18.3% | -18.6% | -45.9% | -17.5% | -18.6% | -54.1% | |
| Net Margin | -62.5% | -110.0% | -108.7% | -24.2% | -20.3% | -34.8% | -17.4% | -17.9% | -46.0% | -17.5% | -18.1% | -54.0% | |
| Pretax Margin | -62.4% | -109.9% | -108.6% | -24.0% | -20.1% | -34.3% | -17.4% | -18.0% | -45.8% | -17.6% | -18.9% | -54.7% | |
| EBITDA Margin | -51.8% | -90.3% | -97.0% | -25.2% | -21.7% | -34.6% | -18.3% | -18.6% | -45.9% | -17.5% | -18.6% | -54.1% | |
| ROA | -29.6% | -45.7% | -39.4% | -13.5% | -9.1% | -13.0% | -10.4% | -16.4% | -51.5% | -21.3% | -16.3% | -35.7% | |
| ROE | -82.8% | -93.0% | -85.6% | -22.5% | -12.8% | -18.4% | -11.5% | -19.6% | -98.6% | -40.8% | -30.8% | -56.3% | |
| ROIC | -46.1% | -61.1% | -78.7% | -24.3% | -13.9% | -14.3% | -11.9% | -20.0% | -92.8% | -44.6% | -32.5% | -71.7% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 4.2 | 2.6 | 3.3 | 4.9 | 7.4 | 7.4 | 3.8 | 1.8 | 2.2 | 2.2 | 2.4 | |
| Quick Ratio | 3.1 | 3.1 | 2.1 | 3.0 | 4.2 | 6.5 | 6.5 | 3.6 | 1.7 | 2.0 | 2.1 | 2.2 | |
| Debt / Equity | 0.8 | 0.4 | · | · | · | · | · | · | 0.0 | · | · | · | |
| LT Debt / Equity | 0.8 | 0.4 | · | · | · | · | · | · | 0.0 | · | · | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.6 | 0.4 | 0.4 | 0.6 | 0.9 | 1.1 | 1.2 | 0.9 | 0.7 | |
| Inventory Turnover | 5.2 | 7.3 | 5.4 | 23.9 | 20.9 | 20.6 | 32.6 | 15.5 | 15.4 | 10.7 | 5.5 | 6.7 | |
| Receivables Turnover | · | · | 3.3 | 4.9 | 5.4 | 6.0 | 6.7 | 5.3 | 5.6 | 7.4 | 7.5 | 7.6 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.56 | $0.82 | $1.24 | $2.20 | $2.52 | $2.65 | $1.79 | $1.03 | $0.51 | $0.46 | $0.57 | $0.67 | |
| Revenue / Share | $0.81 | $0.81 | $1.03 | $2.12 | $1.62 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.22 | $-0.67 | $-0.77 | $0.17 | $-0.22 | · | · | · | · | · | · | · | |
| Cash / Share | $0.56 | $0.24 | $0.93 | $1.73 | $1.79 | $2.32 | $1.54 | $0.97 | $0.65 | $0.47 | $0.58 | $0.67 | |
| EPS (TTM) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 18.6% | -15.4% | -49.4% | 32.3% | 51.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -20.2% | -17.3% | 0.52% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 0.38% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $70M | $59M | $70M | $139M | $105M | $69M | $68M | $61M | $50M | $49M | $42M | $35M | |
| Net Income TTM | $-44M | $-65M | $-76M | $-34M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Market Cap | $147M | $390M | $213M | $307M | $2.04B | $1.40B | $941M | $912M | $404M | $190M | $171M | $100M | |
| Enterprise Value | $109M | $346M | · | · | · | · | · | · | $373M | · | · | · | |
| P/E | -3.3 | -5.4 | -2.7 | -9.1 | -94.8 | -54.6 | -76.1 | · | · | · | · | · | |
| P/S | 2.1 | 6.6 | 3.0 | 2.2 | 19.4 | 20.3 | 13.8 | 15.0 | 8.1 | 3.9 | 4.1 | 2.8 | |
| P/B | 2.9 | 5.8 | 2.5 | 2.1 | 12.4 | 8.2 | 8.9 | 16.2 | 16.5 | 9.9 | 7.5 | 3.8 | |
| P / Tangible Book | 3.1 | 6.1 | 2.5 | 2.2 | 12.6 | 8.4 | · | · | · | · | · | · | |
| P / Cash Flow | -7.6 | -7.9 | -4.1 | 27.2 | -142.7 | -85.2 | -75.0 | -64.7 | -46.1 | -70.3 | -394.1 | 310.6 | |
| P / FCF | -6.2 | -7.3 | -3.7 | 103.0 | -72.5 | -69.4 | -57.8 | -54.1 | -41.4 | -52.9 | -104.6 | 5247.3 | |
| EV / EBITDA | -3.0 | -6.5 | · | · | · | · | · | · | -16.2 | · | · | · | |
| EV / FCF | -4.6 | -6.4 | · | · | · | · | · | · | -38.3 | · | · | · | |
| EV / Revenue | 1.6 | 5.8 | · | · | · | · | · | · | 7.5 | · | · | · | |
| Earnings Yield | -30.7% | -18.7% | -36.7% | -10.9% | -1.1% | -1.8% | -1.3% | · | · | · | · | · |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $15M | $39M | $9M | $15M | $8M | $21M | $13M | $8M | $17M | $27M | $9M | $21M | $13M | $30M | $34M | |
| Cost of Revenue | $4M | $2M | $2M | $2M | $2M | $3M | $4M | $4M | $3M | $5M | $3M | $2M | $3M | $5M | $8M | $10M | |
| R&D Expense | $12M | $11M | $12M | $14M | $14M | $13M | $12M | $12M | $11M | $11M | $11M | $14M | $17M | $17M | $20M | $22M | |
| SG&A Expense | $11M | $10M | $11M | $11M | $12M | $12M | $13M | $14M | $16M | $13M | $12M | $12M | $13M | $15M | $12M | $13M | |
| Operating Expenses | $26M | $23M | $28M | $28M | $28M | $28M | $29M | $29M | $31M | $29M | $26M | $41M | $34M | $37M | $44M | $45M | |
| Operating Income | $-11M | $-8M | $11M | $-19M | $-13M | $-20M | $-7M | $-17M | $-23M | $-12M | $282.0K | $-32M | $-13M | $-24M | $-13M | $-11M | |
| Interest Income | $535.0K | $665.0K | $656.0K | $634.0K | $584.0K | $751.0K | $940.0K | $849.0K | $972.0K | $909.0K | $906.0K | $1M | $1M | $1M | $823.0K | $436.0K | |
| Other Non-op | $-1M | $-1M | $-2M | $-1M | $-984.0K | $-942.0K | $-4M | $-5M | $-985.0K | $-516.0K | $-8M | $-4M | $-9.0K | $-25.0K | $-26.0K | $216.0K | |
| Pretax Income | $-12M | $-9M | $10M | $-20M | $-13M | $-21M | $-10M | $-21M | $-23M | $-11M | $-7M | $-35M | $-12M | $-23M | $-12M | $-10M | |
| Income Tax | $10.0K | $36.0K | $18.0K | $8.0K | $10.0K | $11.0K | $4.0K | $10.0K | $10.0K | $10.0K | $35.0K | $9.0K | $9.0K | $16.0K | $151.0K | $8.0K | |
| Net Income | $-12M | $-9M | $10M | $-20M | $-13M | $-21M | $-10M | $-21M | $-23M | $-12M | $-7M | $-35M | $-12M | $-23M | $-13M | $-10M | |
| EPS (Basic) | $-0.13 | $-0.10 | $0.13 | $-0.22 | $-0.16 | $-0.25 | $-0.12 | $-0.29 | $-0.32 | $-0.16 | $-0.11 | $-0.50 | $-0.17 | $-0.34 | $-0.19 | $-0.15 | |
| EPS (Diluted) | $-0.13 | $-0.10 | $0.13 | $-0.22 | $-0.16 | $-0.25 | $-0.12 | $-0.29 | $-0.32 | $-0.16 | $-0.11 | $-0.50 | $-0.17 | $-0.34 | $-0.19 | $-0.15 | |
| Shares (Basic) | 91,053,000 | 90,768,000 | · | 90,251,000 | 85,389,000 | 82,410,000 | · | 72,032,000 | 70,376,000 | 69,854,000 | · | 69,466,000 | 67,573,000 | 65,931,000 | · | 65,426,000 | |
| Shares (Diluted) | 91,053,000 | 90,768,000 | · | 90,251,000 | 85,389,000 | 82,410,000 | · | 72,032,000 | 70,376,000 | 69,854,000 | · | 69,466,000 | 67,573,000 | 65,931,000 | · | 65,426,000 | |
| EBITDA | $-11M | · | · | $-19M | $-13M | $-19M | · | $-17M | $-23M | $-12M | · | $-32M | $-13M | $-24M | · | $-11M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27M | $37M | $51M | $25M | $27M | $18M | $19M | $37M | $19M | $58M | $65M | $75M | $92M | $103M | $114M | $109M | |
| Short-term Investments | $28M | $29M | $27M | $33M | $40M | $41M | $54M | $53M | $55M | $27M | · | · | · | · | · | · | |
| Inventory | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Prepaid Expense | $3M | $4M | $6M | $5M | $3M | $4M | $4M | $3M | $3M | $5M | · | $5M | $4M | $5M | · | $5M | |
| Other Current Assets | $500.0K | $400.0K | $500.0K | $500.0K | $100.0K | $500.0K | $500.0K | $300.0K | $900.0K | $500.0K | · | · | · | · | · | · | |
| Current Assets | $72M | $80M | $97M | $76M | $89M | $78M | $99M | $113M | $91M | $108M | · | $103M | $120M | $130M | · | $146M | |
| PP&E (Net) | $12M | $13M | $13M | $14M | $15M | $16M | $14M | $13M | $14M | $15M | · | $15M | $23M | $24M | · | $23M | |
| PP&E (Gross) | $59M | $59M | $58M | $58M | $58M | $57M | $55M | $54M | $54M | $55M | · | $54M | $66M | $65M | · | $63M | |
| Accum. Depreciation | $47M | $46M | $45M | $44M | $43M | $42M | $41M | $41M | $40M | $40M | · | $39M | $42M | $41M | · | $39M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $3M | $3M | $3M | $3M | |
| Other Non-current Assets | $1M | $994.0K | $883.0K | $912.0K | $950.0K | $967.0K | $1M | $2M | $2M | $1M | · | $726.0K | $498.0K | $415.0K | · | $208.0K | |
| Total Assets | $120M | $129M | $148M | $124M | $138M | $129M | $149M | $148M | $132M | $150M | · | $154M | $207M | $218M | · | $235M | |
| Accounts Payable | $3M | $2M | $2M | $2M | $1M | $6M | $3M | $4M | $4M | $3M | · | $3M | $4M | $4M | · | $3M | |
| Accrued Liabilities | $3M | $3M | $3M | $3M | $3M | $5M | $6M | $7M | $5M | $5M | · | $9M | $7M | $8M | · | $13M | |
| Current Liabilities | $24M | $15M | $25M | $18M | $15M | $21M | $24M | $35M | $31M | $29M | · | $38M | $36M | $38M | · | $32M | |
| Capital Leases | $28M | $29M | $30M | $26M | $27M | $27M | $28M | $9M | $10M | $11M | · | $13M | $35M | $37M | · | $40M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Total Liabilities | $87M | $86M | $97M | $85M | $83M | $79M | $82M | $75M | $71M | $70M | · | $63M | $83M | $92M | · | $81M | |
| Long-term Debt | $41M | $40M | $40M | $40M | $39M | $29M | · | $29M | $28M | $28M | · | · | · | · | · | · | |
| Total Debt | $41M | · | · | $40M | $39M | $29M | · | $29M | $28M | $28M | · | · | · | · | · | · | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Paid-in Capital | $660M | $659M | $657M | $655M | $652M | $633M | $630M | $626M | $593M | $588M | · | $582M | $580M | $570M | · | $563M | |
| Retained Earnings | $-627M | $-615M | $-607M | $-616M | $-597M | $-583M | $-563M | $-552M | $-532M | $-509M | · | $-490M | $-455M | $-444M | · | $-409M | |
| AOCI | $-13.0K | $-11.0K | $8.0K | $12.0K | $-3.0K | $14.0K | $52.0K | $126.0K | $-23.0K | $-16.0K | · | · | · | · | · | · | |
| Stockholders' Equity | $33M | $43M | $51M | $39M | $56M | $50M | $67M | $73M | $61M | $79M | $87M | $92M | $124M | $126M | $145M | $154M | |
| Liabilities + Equity | $120M | $129M | $148M | $124M | $138M | $129M | $149M | $148M | $132M | $150M | · | $154M | $207M | $218M | · | $235M | |
| Shares Outstanding | 91,388,000 | 90,894,000 | 90,478,000 | 90,281,000 | 90,254,000 | 82,841,000 | 81,850,000 | 81,376,000 | 70,914,000 | 70,554,000 | · | 69,827,000 | 69,804,000 | 66,696,000 | · | 65,613,000 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | · | · | · | |
| Stock-based Comp | $2M | $1M | $2M | $3M | $3M | $2M | $3M | $3M | $5M | $3M | $2M | $2M | $3M | $3M | $3M | $5M | |
| Restructuring | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $3M | $72.0K | $72.0K | $3M | $0 | |
| Other Non-cash | · | · | · | · | · | $3M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-13M | $20M | $-8M | $-18M | $-14M | $-16M | $-13M | $-12M | $-8M | $-11M | $-16M | $-16M | $-9M | $5M | $20M | |
| CapEx | $898.0K | $176.0K | $520.0K | $182.0K | $3M | $1M | $2M | $1M | $395.0K | $1M | $-380.0K | $678.0K | $2M | $3M | $-33.0K | $1M | |
| Investing Cash Flow | $175.0K | $-1M | $6M | $6M | $-367.0K | $12M | $-3M | $2M | $-27M | $-29M | $1M | $-1M | $-2M | $-3M | $33.0K | $-1M | |
| Debt Issued | · | · | $0 | $0 | $10M | $0 | $0 | $0 | $0 | $30M | $0 | $0 | $0 | $0 | · | · | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $30M | · | · | · | · | · | · | |
| Stock Issued | · | · | $-1.0K | $0 | · | · | $-1.0K | $31M | $0 | $0 | $0 | $0 | $7M | $2M | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $2M | · | · | |
| Financing Cash Flow | $66.0K | $-14.0K | $180.0K | $-111.0K | $27M | $1M | $1M | $30M | $-197.0K | $29M | $0 | $-108.0K | $7M | $1M | $339.0K | $133.0K | |
| Net Change in Cash | $-9M | $-14M | $26M | $-1M | $8M | $-944.0K | $-18M | $19M | $-39M | $-7M | $-10M | $-18M | $-11M | $-11M | $5M | $19M | |
| Taxes Paid | · | · | · | · | · | $0 | · | · | · | $17.0K | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-15M | · | · | · | $-9M | · | · | · | $-12M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -75.3% | · | · | -220.3% | -83.9% | -271.6% | · | -129.0% | -284.9% | -69.6% | · | -345.6% | -59.2% | -182.3% | · | -30.9% | |
| Net Margin | -80.5% | · | · | -228.1% | -86.6% | -274.3% | · | -160.8% | -285.2% | -67.4% | · | -376.3% | -54.0% | -174.2% | · | -29.0% | |
| Pretax Margin | -80.4% | · | · | -228.0% | -86.5% | -274.1% | · | -160.8% | -285.1% | -67.3% | · | -376.2% | -54.0% | -174.1% | · | -29.0% | |
| EBITDA Margin | -75.3% | · | · | -220.3% | -83.9% | -255.8% | · | -129.0% | -284.9% | -69.6% | · | -345.6% | -59.2% | -182.3% | · | -30.9% | |
| ROA | -9.3% | · | · | -14.4% | -9.8% | -14.9% | · | -13.6% | -13.4% | -6.3% | · | -17.9% | -5.2% | -10.0% | · | -4.3% | |
| ROE | -27.1% | · | · | -35.0% | -22.7% | -32.1% | · | -25.0% | -24.5% | -11.2% | · | -28.4% | -8.1% | -15.9% | · | -6.2% | |
| ROIC | -15.2% | · | · | -24.2% | -13.6% | -26.0% | · | -16.2% | -25.3% | -11.1% | · | -35.0% | -10.2% | -18.8% | · | -6.9% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | · | · | 4.1 | 5.8 | 3.7 | · | 3.2 | 3.0 | 3.7 | · | 2.7 | 3.4 | 3.4 | · | 4.6 | |
| Quick Ratio | 2.3 | · | · | 3.2 | 4.4 | 2.9 | · | 2.6 | 2.4 | 2.9 | · | 1.9 | 2.6 | 2.7 | · | 3.4 | |
| Debt / Equity | 1.2 | · | · | 1.0 | 0.7 | 0.6 | · | 0.4 | 0.5 | 0.4 | · | · | · | · | · | · | |
| LT Debt / Equity | 1.0 | · | · | 1.0 | 0.7 | 0.6 | · | 0.4 | 0.5 | 0.4 | · | · | · | · | · | · |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.1 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 2.0 | · | · | 1.2 | 1.0 | 1.3 | · | 2.0 | 1.6 | 2.2 | · | 1.1 | 1.7 | 2.5 | · | 7.2 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.36 | · | · | $0.43 | $0.62 | $0.60 | · | $0.90 | $0.87 | $1.12 | · | $1.31 | $1.78 | $1.89 | · | $2.35 | |
| Revenue / Share | $0.16 | · | · | $0.10 | $0.18 | $0.09 | · | $0.18 | $0.11 | $0.24 | · | $0.13 | $0.32 | $0.20 | · | $0.53 | |
| Cash Flow / Share | · | · | · | · | · | $-0.17 | · | · | · | $-0.11 | · | · | · | $-0.14 | · | · | |
| Cash / Share | $0.30 | · | · | $0.28 | $0.30 | $0.22 | · | $0.46 | $0.26 | $0.82 | · | $1.07 | $1.32 | $1.54 | · | $1.66 | |
| EPS (TTM) | $-0.32 | $-0.73 | · | $-0.75 | $-0.82 | $-0.98 | · | $-0.88 | $-1.09 | $-0.94 | · | $-1.20 | $-0.85 | $-0.72 | · | $-0.47 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78M | $47M | · | $53M | $57M | $50M | · | $64M | $61M | $74M | · | $74M | $99M | $116M | · | $133M | |
| Net Income TTM | $-31M | $-62M | · | $-64M | $-65M | $-74M | · | $-62M | $-76M | $-65M | · | $-82M | $-57M | $-48M | · | $-31M | |
| Market Cap | $207M | · | · | $220M | $220M | $223M | · | $251M | $220M | $246M | · | $132M | $195M | $276M | · | $398M | |
| Enterprise Value | $192M | · | · | $201M | $193M | $192M | · | $189M | $175M | $189M | · | · | · | · | · | · | |
| P/E | -7.1 | -2.2 | · | -3.3 | -3.0 | -2.7 | · | -3.5 | -2.8 | -3.7 | · | -1.6 | -3.3 | -5.8 | · | -12.9 | |
| P/S | 2.7 | · | · | 4.2 | 3.9 | 4.5 | · | 3.9 | 3.6 | 3.3 | · | 1.8 | 2.0 | 2.4 | · | 3.0 | |
| P/B | 6.3 | · | · | 5.7 | 4.0 | 4.5 | · | 3.4 | 3.6 | 3.1 | · | 1.4 | 1.6 | 2.2 | · | 2.6 | |
| P / Tangible Book | 6.8 | 3.6 | · | 6.1 | 4.1 | 4.7 | · | 3.5 | 3.7 | 3.2 | · | 1.5 | 1.6 | 2.2 | · | 2.6 | |
| P / Cash Flow | · | · | · | · | · | -16.2 | · | · | · | -31.6 | · | · | · | -30.0 | · | · | |
| EV / Revenue | 2.5 | · | · | 3.8 | 3.4 | 3.9 | · | 2.9 | 2.9 | 2.5 | · | · | · | · | · | · | |
| Earnings Yield | -14.2% | -44.8% | · | -30.7% | -33.6% | -36.4% | · | -28.6% | -35.2% | -26.9% | · | -63.5% | -30.4% | -17.4% | · | -7.8% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $70M | $59M | $70M | $139M | $105M |
| Marża Operacyjna % | -59.3% | -98.6% | -97.0% | -25.2% | -21.7% |
| Zysk netto | $-44M | $-65M | $-76M | $-34M | $-21M |
| Rozwodniony EPS | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.8 | 0.4 | · | · | · |
| Wskaźnik bieżący | 3.8 | 4.2 | 2.6 | 3.3 | 4.9 |
| Wskaźnik Szybkości | 3.1 | 3.1 | 2.1 | 3.0 | 4.2 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-24M | $-54M | $-57M | $3M | $-28M |
Właściciele instytucjonalni (13F) 155 emitentów · $154.0M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
155
Wartość posiadanych akcji
$154.0M
Nowe pozycje
29
Zamknięte pozycje
11
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 29 (-4 vs poprzedni kw.) | 11 (-10 vs poprzedni kw.) | 61 (+13 vs poprzedni kw.) | 36 (+4 vs poprzedni kw.) | +3.0M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $16 462 635 | 7 284 352 | 10,69% | Akcje |
| Opaleye Management Inc. | $15 334 100 | 6 785 000 | 9,96% | Akcje |
| Aberdeen Group plc | $15 300 096 | 6 769 954 | 9,94% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $12 541 054 | 5 549 139 | 8,15% | Akcje |
| Telemark Asset Management, LLC | $8 692 889 | 3 846 411 | 5,65% | Akcje |
| AMERIPRISE FINANCIAL INC | $8 609 334 | 3 809 440 | 5,59% | Akcje |
| Nantahala Capital Management, LLC | $8 189 365 | 3 623 613 | 5,32% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $8 174 666 | 3 617 109 | 5,31% | Akcje |
| VANGUARD GROUP INC | $8 054 714 | 4 941 542 | 5,23% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $4 887 990 | 2 162 393 | 3,17% | Akcje |
| STATE STREET CORP | $3 970 400 | 1 756 814 | 2,58% | Akcje |
| D. E. Shaw & Co., Inc. | $3 032 952 | 1 342 014 | 1,97% | Akcje |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $3 006 263 | 1 330 205 | 1,95% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 954 206 | 1 307 171 | 1,92% | Akcje |
| Assenagon Asset Management S.A. | $2 888 746 | 1 278 206 | 1,88% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $1 910 675 | 845 431 | 1,24% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $1 574 314 | 696 599 | 1,02% | Akcje |
| NORTHERN TRUST CORP | $1 543 444 | 682 940 | 1,00% | Akcje |
| FRANKLIN RESOURCES INC | $1 533 726 | 678 640 | 1,00% | Akcje |
| MORGAN STANLEY | $1 467 125 | 649 170 | 0,95% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $1 313 191 | 581 058 | 0,85% | Akcje |
| Man Group plc | $1 278 240 | 565 593 | 0,83% | Akcje |
| Post Resch Tallon Group Inc. | $1 273 460 | 563 478 | 0,83% | Akcje |
| PERKINS CAPITAL MANAGEMENT INC | $1 188 986 | 526 100 | 0,77% | Akcje |
| FMR LLC | $1 081 371 | 478 483 | 0,70% | Akcje |
| GOLDMAN SACHS GROUP INC | $982 929 | 434 924 | 0,64% | Akcje |
| ALGERT GLOBAL LLC | $973 857 | 430 910 | 0,63% | Akcje |
| Nuveen, LLC | $886 524 | 392 267 | 0,58% | Akcje |
| TUDOR INVESTMENT CORP ET AL | $808 910 | 357 925 | 0,53% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $708 690 | 313 386 | 0,46% | Akcje |
| Russell Investments Group, Ltd. | $696 292 | 308 095 | 0,45% | Akcje |
| PLATINUM INVESTMENT MANAGEMENT LTD | $597 689 | 264 464 | 0,39% | Akcje |
| ROYAL BANK OF CANADA | $594 000 | 262 926 | 0,39% | Akcje |
| Potomac Capital Management, Inc. | $587 600 | 260 000 | 0,38% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $547 397 | 242 211 | 0,36% | Akcje |
| XTX Topco Ltd | $543 817 | 240 627 | 0,35% | Akcje |
| BANK OF AMERICA CORP /DE/ | $543 568 | 240 517 | 0,35% | Akcje |
| UBS Group AG | $542 190 | 239 907 | 0,35% | Akcje |
| Bank of New York Mellon Corp | $510 849 | 226 039 | 0,33% | Akcje |
| CITADEL ADVISORS LLC | $432 971 | 191 580 | 0,28% | Akcje |
| Invesco Ltd. | $366 732 | 162 271 | 0,24% | Akcje |
| Cubist Systematic Strategies, LLC | $359 610 | 147 381 | 0,23% | Akcje |
| BARCLAYS PLC | $350 920 | 155 274 | 0,23% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $334 595 | 148 051 | 0,22% | Akcje |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $284 552 | 125 908 | 0,18% | Akcje |
| STRS OHIO | $273 460 | 121 000 | 0,18% | Akcje |
| JANE STREET GROUP, LLC | $273 042 | 120 815 | 0,18% | Akcje |
| MARSHALL WACE, LLP | $264 726 | 117 135 | 0,17% | Akcje |
| Stonepine Capital Management, LLC | $247 836 | 109 662 | 0,16% | Akcje |
| RHUMBLINE ADVISERS | $233 449 | 103 301 | 0,15% | Akcje |
Aktywiści i właściciele 5%+ 3 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| John Nicols | 16 lutego 2021 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| – I.RS. IDENTIFICATION NO. OF ABOVE PERSON RAÍZEN ENERGIA S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON SHELL BRAZIL HOLDING B.V., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ROYAL DUTCH SHELL PLC, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN S.A. INDUSTRIA E COMÉRCIO, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN INVESTIMENTOS E PARTICIPAÇÕES S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN LIMITED ×2 zgłoszenia | 26 maja 2015 | · | Pierwotne zgłoszenie | · | SEC |
| – I.RS. IDENTIFICATION NO. OF ABOVE PERSON RAIZEN ENERGIA PARTICIPA Ç Õ ES S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ISPAGNAC PARTICIPA Ç Õ ES LTDA., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ROYAL DUTCH SHELL PLC, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN S.A. INDUSTRIA E COM É RCIO, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN LIMITED | 7 czerwca 2011 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 44 insiderów · 19 dyrektorzy generalni · 22 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Alison Moore | President and CEO | 23 lutego 2026 A | 250 506 | 0 | 2 | $-20 672 |
| Peter M Strumph | Interim President and CEO | 1 czerwca 2012 A | 60 756 | 0 | 0 | $0 |
| Alan Shaw | President and CEO | 16 grudnia 2011 S | 202 000 | 0 | 0 | $0 |
| Georgia Erbez | Chief Financial Officer and Chief Business Officer | 23 lutego 2026 A | 66 810 | 0 | 2 | $-20 610 |
| Sriram Ryali | Chief Financial Officer | 1 stycznia 2024 A | 175 791 | 0 | 0 | $0 |
| Gordon Sangster | SVP & Chief Financial Officer | 21 marca 2019 M | 134 453 | 0 | 0 | $0 |
| David D O'Toole | SVP & Chief Financial Officer | 4 września 2013 F | 110 687 | 0 | 0 | $0 |
| Brian Paul Dowd | Interim CFO | 1 czerwca 2012 A | 28 310 | 0 | 0 | $0 |
| Robert J Lawson | SVP and CFO | 11 maja 2011 P | 44 000 | 0 | 0 | $0 |
| Kevin Norrett | Chief Operating Officer | 5 lutego 2025 A | 177 327 | 0 | 0 | $0 |
| Stefan Lutz | Chief Scientific Officer | 23 lutego 2026 A | 130 421 | 0 | 3 | $-17 853 |
| Margaret Nell Fitzgerald | Chief Legal and Compliance Officer | 1 stycznia 2024 A | 133 770 | 0 | 0 | $0 |
| James Lalonde | SVP, R&D | 14 maja 2019 M | 133 402 | 0 | 0 | $0 |
| Michael D. Aldridge | Senior Vice President, Corporate & Strategic Development | 17 maja 2018 M | 0 | 0 | 0 | $0 |
| Douglas T. Sheehy | EVP, Chief Administrative Officer, General Counsel & Secretary | 5 marca 2016 F | 247 617 | 0 | 0 | $0 |
| Matthew Tobin | SVP, Research & Development | 16 maja 2013 M | 78 707 | 0 | 0 | $0 |
| David L. Anton | SVP, BioIndustrials | 10 lutego 2013 F | 93 777 | 0 | 0 | $0 |
| Seufer-Wasserthal Peter | SVP, Pharmaceuticals | 24 stycznia 2013 A | 93 064 | 0 | 0 | $0 |
| Joseph J. Sarret | SVP and CBO | 7 marca 2012 A | 74 000 | 0 | 0 | $0 |
| Raymond De Vre | Dyrektor | 17 czerwca 2026 A | 84 811 | 0 | 2 | $-8 633 |
| Esther Martinborough | Dyrektor | 17 czerwca 2026 A | 129 036 | 0 | 0 | $0 |
| Christos Richards | Dyrektor | 17 czerwca 2026 A | 85 133 | 0 | 0 | $0 |
| Cynthia Collins | Dyrektor | 17 czerwca 2026 A | 112 157 | 0 | 0 | $0 |
| Stephen George Dilly | Dyrektor | 17 czerwca 2026 A | 727 053 | 0 | 0 | $0 |
| Rahul Singhvi | Dyrektor | 17 czerwca 2026 A | 137 052 | 0 | 0 | $0 |
| David V Smith | Dyrektor | 17 czerwca 2026 A | 105 705 | 0 | 0 | $0 |
| PARKER H STEWART | Dyrektor | 17 czerwca 2026 A | 143 583 | 0 | 0 | $0 |
| Dennis P Wolf | Dyrektor | 21 listopada 2025 S | 138 951 | 0 | 1 | $-13 965 |
| Byron L Dorgan | Dyrektor | 11 czerwca 2024 A | 223 581 | 0 | 0 | $0 |
| Jennifer Aaker | Dyrektor | 13 czerwca 2023 A | 66 211 | 0 | 0 | $0 |
| John J Nicols | Dyrektor | 18 kwietnia 2023 M | 783 965 | 0 | 0 | $0 |
| Patrick Y Yang | Dyrektor | 14 czerwca 2022 A | 53 785 | 0 | 0 | $0 |
| Bernard J Kelley | Dyrektor | 10 sierpnia 2021 M | 206 136 | 0 | 0 | $0 |
| Thomas R Baruch | Dyrektor | 12 czerwca 2020 S | 33 093 | 0 | 0 | $0 |
| Pam P. Cheng | Dyrektor | 11 czerwca 2019 A | 69 589 | 0 | 0 | $0 |
| Kathleen Sereda Glaub | Dyrektor | 11 czerwca 2019 A | 68 481 | 0 | 0 | $0 |
| Alexander Karsner | Dyrektor | 2 stycznia 2014 A | 78 519 | 0 | 0 | $0 |
| Bruce A Pasternack | Dyrektor | 24 sierpnia 2010 P | 10 000 | 0 | 0 | $0 |
| James R Sulat | Dyrektor | 27 kwietnia 2010 J | 5 957 108 | 0 | 0 | $0 |
| Opaleye Management Inc. | Posiadacz 10% | 1 grudnia 2025 S | 179 989 | 0 | 27 | $-7 596 890 |
| Brazil Holding B.V. Shell | Posiadacz 10% | 31 maja 2011 J | 5 573 319 | 0 | 0 | $0 |
| Equilon Enterprises LLC | Posiadacz 10% | 20 maja 2011 J | 5 573 319 | 0 | 0 | $0 |
| MAXYGEN INC | Posiadacz 10% | 14 grudnia 2010 J | 524 643 | 0 | 0 | $0 |
| Dean Ross Taylor JR | · | 7 lutego 2023 F | 38 554 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 19 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,42% | 70 133 SH | 2 października 2026 | Dziennie |
| IWC · iShares Trust | 0,03% | 288 891 SH | 11 września 2026 | Dziennie |
| IBB · iShares Trust | 0,01% | 766 290 SH | 11 września 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 496 936 SH | 19 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 78 444 SH | 19 sierpnia 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,01% | 7 738 SH | 1 października 2026 | Dziennie |
| IWO · iShares Trust | 0,01% | 696 097 SH | 11 września 2026 | Dziennie |
| IWM · iShares Trust | 0,00% | 2 244 630 SH | 11 września 2026 | Dziennie |
| RSSL · Global X Funds | 0,00% | 41 308 NS | 31 lipca 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,00% | 69 999 SH | 2 października 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,00% | 52 788 NS | 31 lipca 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 17 106 SH | 3 września 2026 | Dziennie |
| DFAC · Dimensional ETF Trust | 0,00% | 19 277 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1 729 NS | 31 lipca 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 895 869 SH | 19 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2 633 770 SH | 19 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9 454 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 6 744 SH | 19 sierpnia 2026 | Dziennie |
| IWN · iShares Trust | · | 129 318 SH | 11 września 2026 | Dziennie |
CDXS Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 13 analityków
KUP
Średni cel
$5.00
+267,6%
4 30,8%
Mocne kupno
6 46,2%
Kup
3 23,1%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
7 analityków · 2026-10-01Średnia cel $6.14 +351,7%
← Poniżej wszystkich celów
Aktualna cena $1.36
Niski$2.00
Średnia$6.14
Wysoki$11.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| CDXS | $147M | -3.3 | 18.6% | -62.5% | -82.8% | · |
| LAB | $495M | -6.4 | -6.2% | -87.8% | -17.6% | 49.9% |
| QSI | · | · | · | · | · | · |
| LFCR | $249M | -5.3 | 0.47% | -30.0% | -461.3% | 31.3% |
| NAUT | $247M | -4.1 | · | · | -34.9% | · |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| SEER | · | -1.4 | 17.0% | · | · | · |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | · |
| HYFT | · | · | · | -89.7% | -78.9% | 58.8% |
| CIRC | · | · | · | · | · | · |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 11, 2026